Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy.

NCTID NCT06392724 (View at clinicaltrials.gov)
Description
Development Status Active
Indication Duchenne Muscular Dystrophy (DMD)
Disease Ontology Term DOID:11723
Compound Name GEN6050X
Sponsor Peking Union Medical College Hospital
Funder Type Other
Recruitment Status
Recruiting
Enrollment Count 3
Results Posted Not Available

Therapy Information

Target Gene/Variant DMD
Therapy Type Gene editing
Therapy Route In-vivo
Mechanism of Action Exon skipping/splice editor
Route of Administration Intravenous
Drug Product Type Viral vector
Target Tissue/Cell
Delivery System Viral transduction
Vector Type dual AAV9
Editor Type eTAM
Dose 1 5E13 vg/kg body weight
Dose 2
Dose 3
Dose 4
Dose 5

Study Record Dates

Current Stage Early phase1
Submit Date 2024-04-26
Completion Date 2027-12
Last Update 2024-07-08

Participation Criteria

Eligible Age 4 Years - 10 Years
Standard Ages Child
Sexes Eligible for Study MALE

Locations

No.of Trial Sites 1
Locations China

Regulatory Information

Has US IND False
FDA Designations
Recent Updates Drug is being developed by GenAssist Ltd

Resources/Links

News and Press Releases
Preclinical Publications